Venus Remedies bags recognition for in-house R&D excellence

The company invested 3.53 per cent of its total sales in R&D, from which it has generated 5.25 per cent of its total revenue, which stood at Rs 575.18 crore in FY 2021-22 Venus Remedies announced the renewal of recognition for its in-house Research and Development (R&D) unit by the Department of Scientific and Industrial Research (DSIR), Ministry of Science & Technology, Government of India. This renewal underscores Venus Remedies' commitment to innovation, excellence in research, and its significant contributions to healthcare. The company invested 3.53 per cent of its total sales in R&D, from which it has generated 5.25 per cent of its total revenue, which stood at Rs 575.18 crore in FY 2021-22. The R&D spend for the same period amounted to Rs 20.31 crores. "Our in-house R&D unit has been at the forefront of pioneering research and development initiatives," said Saransh Chaudhary, CEO, Venus Medicine Research Centre and President of Global Critical Care at Venus Remedies. "This renewal of recognition from DSIR reinforces our position as a research-driven pharmaceutical company dedicated to bringing innovative and effective solutions to address global healthcare needs." With the renewal of recognition from DSIR and its ongoing efforts to combat antimicrobial resistance, Venus Remedies solidifies its position as a leading research-driven pharmaceutical company, dedicated to excellence in research and bringing innovative medical solutions to address global healthcare challenges.